loader2
Partner With Us NRI

Hester Biosciences Ltd share Price

Company details

1,634.50
1,665.00
1,404.55
2,450.00
6M Return -12.09%
1Y Return -26.37%
Mkt Cap.(Cr) 1,402.51
Volume 5,177
Div Yield 0.48%
OI
-
OI Chg %
-
Volume 5,177

Open Free Trading Account Online with ICICIDIRECT

Animal health drives sales as poultry decline continues

About The Stock

    Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania.

    • It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products
    • Revenue segment wise: poultry healthcare:73%, animal healthcare: 27%

Q4FY22

    Numbers were impacted as poultry farm economics turned adverse due to rise in feed costs and decline in end-product prices

    • Sales were down 12% YoY to ₹ 56.5 crore
      • EBITDA was at ₹ 10.3 crore, down 48% YoY with margins at 18.3%. Margins declined amid higher spends on market expansion in the animal health

    Adjusted PAT was at ₹ 7.7 crore (down 41% YoY). [Base of Q4FY21 had ₹ 6.8 crore of license fee income]

Click here for full recommendation

Research view on more stocks

Hester Biosciences Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Hester Biosciences Ltd.

Pharmaceuticals company Hester Biosciences announced Q4FY23 & FY23 results:

Standalone Q4FY23 & FY23:

  • Overall gross profit margin reduced by 1% due to the change in product mix between vaccines and health products, health products sales having gone up.
  • Operating EBITDA increased with the increase in sales.
  • The reduction in EBITDA margin was due to the reduction in Gross Profit margin, accompanied by higher market development costs in animal health division and the new pet division
  • Q4 PAT margin benefited from lower finance costs due to the reversal of unrealized forex loss of Rs 6.46 million on the translation of USD loan in Q4FY23, as against a loss of Rs 5.31 million in Q4FY22. Consequently, PAT increased by 27% from Rs 49.48 million to Rs 62.63 million.

 

Result PDF

View Other Company Results

OUR RESEARCH VIEW

Investment recommendation

Animal health drives sales as poultry decline continues
Call Date
02 Feb 2023
Entry Price 1,790.00
Target Price 1,830.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Hester Biosciences Ltd Stocks COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 259.99 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 2,333.12 37,369.27
LAST 3M 16,668.82 53,102.69
LAST 6M 64,410.78 32,565.35
LAST 12M 119,684.93 75,969.00

Hester Biosciences Ltd Information

Stock PE (TTM)
53.04
Promoter Holding
53.73%
Book Value
328.8249
ROCE
13.29%
ROE
16.17%
Description
  • Incorporated as a private limited company in Apr.`87, Hester Pharmaceutical (HPL) was converted into a public limited company in Nov.`93. HPL markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan; Maine Biological Laboratories, US; Idexx Corporation, US; International Diagnostic Systems Corporation, US; Biogal Galed Laboratories, Israel; and Kemin Europa, Belgium. The company`s own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation. During 1996-97, company successfully implemented veterinary vaccine and commercial production has begun. The company has received licenses for producing 10 additional poultry vaccines.It has also signed an manufacturing agreement with Sinsui Inc for producing poultry vaccines.

Registered Address

1st Flr PushpakPachvati Circle, Motilal Hirabhai Road, Ahmedabad, Gujarat, 380006

Tel : 91-079-26445107
Email : mail:hester.in
Website : http://www.hester.in
Registrar

Sharepro Services India Pvt Lt

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524669
NSE Code : HESTERBIO
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE782E01017

FAQ’s on Hester Biosciences Ltd Shares

You can buy Hester Biosciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Hester Biosciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 31, 2023 03:57 PM the closing price of Hester Biosciences Ltd was ₹ 1,648.65.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 31, 2023 03:57 PM, the market cap of Hester Biosciences Ltd stood at ₹ 1,402.51.

The latest PE ratio of Hester Biosciences Ltd as of May 31, 2023 03:57 PM is 53.04

The latest PB ratio of Hester Biosciences Ltd as of May 31, 2023 03:57 PM is 0.20

The 52-week high of Hester Biosciences Ltd is ₹ 2,450.00 while the 52-week low is ₹ 1,404.55

According to analyst recommendations, Hester Biosciences Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app